Treatment of Hyperuricemia in Essential Hypertension
نویسندگان
چکیده
منابع مشابه
Treatment of hyperuricemia in essential hypertension.
Treatment of Hyperuricemia in Essential Hypertension To the Editor: The 2 recent articles linking an elevated serum uric acid level with an increased risk of developing hypertension are of great interest.1,2 The application of the key finding in these 2 studies, that is, a graded increase in risk of developing essential hypertension based on the serum uric acid level, is likely to be more far r...
متن کاملHyperuricemia in severe pulmonary hypertension.
STUDY OBJECTIVE Hyperuricemia occurs frequently in patients with myeloproliferative and lymphoproliferative disorders and in patients with congenital heart disease associated with polycythemia. Whether hyperuricemia is common in patients with severe pulmonary hypertension is not known. DESIGN, PATIENTS, MEASUREMENTS In the Pulmonary Hypertension Center at the University of Colorado Health Sci...
متن کاملHyperuricemia in childhood primary hypertension.
Experimental animal models suggest that uric acid might have a pathogenic role in the early development of primary hypertension. We hypothesized that serum uric acid is correlated with blood pressure in children with new-onset, untreated, primary hypertension. We evaluated 125 consecutive children referred to the Baylor Pediatric Renal Program for evaluation of hypertension. None of the subject...
متن کاملPropranolol in the treatment of essential hypertension.
In a series of 450 patients with mild essential hypertension, propranolol alone (P), propranolol plus hydrochlorothiazide (P+T), propranolol plus hydralazine (P+H), and propranolol plus hydrochlorothiazide plus hydralazine (P+T+H) were compared to reserpine plus hydrochlorothiazide (R+T). Comparison was based on reduction of diastolic blood pressures (BP) to below 90 mm Hg and at least 5 mm Hg ...
متن کاملEssential hypertension : part II: treatment.
The goal of antihypertensive treatment is to reduce overall CVD risk and thus its morbidity and mortality rates. In any given patient, the decision to begin treatment is governed by the risk of CVD, which is determined by the magnitude of the BP elevation and the presence or absence of target organ disease and/or additional CVD risk factors. Recent consensus committees, including JNC VI and the...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Hypertension
سال: 2007
ISSN: 0194-911X,1524-4563
DOI: 10.1161/hypertensionaha.107.089789